Analysts Set Pediatrix Medical Group, Inc. (NYSE:MD) Price Target at $19.80

Pediatrix Medical Group, Inc. (NYSE:MD) has earned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $19.80.

MD has been the topic of a number of recent analyst reports. Truist Financial cut their price target on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday, February 19th. UBS Group lowered their price objective on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a research note on Tuesday, February 24th. Zacks Research cut Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 23rd. Jefferies Financial Group upgraded Pediatrix Medical Group to a “strong-buy” rating in a report on Thursday, March 12th. Finally, Deutsche Bank Aktiengesellschaft set a $19.00 price target on Pediatrix Medical Group in a research report on Friday, February 20th.

Hedge Funds Weigh In On Pediatrix Medical Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Global Retirement Partners LLC boosted its holdings in Pediatrix Medical Group by 68,250.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock valued at $29,000 after acquiring an additional 1,365 shares in the last quarter. Transamerica Financial Advisors LLC bought a new position in Pediatrix Medical Group in the 4th quarter worth $30,000. Eurizon Capital SGR S.p.A. bought a new position in Pediatrix Medical Group in the 4th quarter worth $33,000. Blue Trust Inc. purchased a new stake in shares of Pediatrix Medical Group in the 4th quarter worth about $37,000. Finally, TD Private Client Wealth LLC purchased a new stake in shares of Pediatrix Medical Group in the 4th quarter worth about $39,000. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Performance

Shares of MD stock opened at $21.19 on Friday. The company has a market capitalization of $1.76 billion, a P/E ratio of 10.92 and a beta of 0.72. Pediatrix Medical Group has a fifty-two week low of $11.84 and a fifty-two week high of $24.99. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.66 and a current ratio of 1.66. The stock has a 50 day moving average price of $20.46 and a two-hundred day moving average price of $20.44.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Thursday, February 19th. The company reported $0.50 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by ($0.03). Pediatrix Medical Group had a return on equity of 19.59% and a net margin of 8.64%.The firm had revenue of $493.77 million during the quarter, compared to the consensus estimate of $486.23 million. During the same quarter in the prior year, the business posted $0.51 EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. Analysts expect that Pediatrix Medical Group will post 1.38 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.